In a recent study published in the IJIR: Your Sexual Medicine Journal , researchers assess the risk of erectile dysfunction (ED) in obese and non-diabetic men following semaglutide treatment. Study: Prescribing semaglutide for weight loss in non-diabetic, obese patients is associated with an increased risk of erectile dysfunction: a TriNetX database study. Image Credit: Korawat photo shoot / Shutterstock.
com Semaglutide is an incretin mimetic medication that increases the release of insulin from the pancreas and, as a result, is used to treat type 2 diabetes (T2D) and obesity. Currently, semaglutide is considered one of the most effective anti-obesity interventions, with some scientists describing the United States Food and Drug Administration (FDA) approval of this drug as a "paradigm shift" in anti-obesity treatment. In addition to its T2D and obesity benefits, semaglutide has been clinically validated to reduce the risk of cardiovascular disease, myocardial infarction, and strokes in obese men and women.
Despite these benefits, semaglutide use has been associated with sexual dysfunction, particularly in non-diabetic men. Nevertheless, additional research is needed to determine the risk of this side effect in patients prescribed semaglutide. As semaglutide gains traction for its role in weight loss, a nuanced exploration of its known side effects becomes imperative.
" In the present study, researchers assess sexual dysfunction risks associated with semaglutide use by non-dia.
